Kathryn M. Curtis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kathryn M. Curtis has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Polly A. Marchbanks
12 shared publicationsMaura K. Whiteman
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
9 shared publicationsHerbert B. Peterson
7 shared publicationsNaomi K. Tepper
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
7 shared publications- Denise J. Jamieson
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
5 shared publications Lauren B. Zapata
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
5 shared publications
Latest Publications
- 15 July 2025
- Published by Elsevier in Contraception
- Vol. 159, 111015
Using updated clinical recommendations to support contraceptive decision-making: U.S. medical eligibility criteria for contraceptive use, 2024
- 15 July 2025
- Published by Elsevier in Contraception
- Vol. 159, 111015
Using updated clinical recommendations to support contraceptive decision-making: U.S. medical eligibility criteria for contraceptive use, 2024
- 22 May 2025
- Published by Elsevier in Contraception
- Vol. 159, 110971
Smooth muscle relaxants for intrauterine device placement: A systematic review
- 22 May 2025
- Published by Elsevier in Contraception
- Vol. 159, 110971
Smooth muscle relaxants for intrauterine device placement: A systematic review
- 5 April 2025
- Published by Elsevier in Contraception
- Vol. 159, 110898
Hormonal contraception after use of ulipristal acetate as emergency contraception: A systematic review
- 5 April 2025
- Published by Elsevier in Contraception
- Vol. 159, 110898
Hormonal contraception after use of ulipristal acetate as emergency contraception: A systematic review
- Top Cited PapersOpen Access
- 8 August 2024
- Published by Centers for Disease Control MMWR Office in MMWR. Recommendations and Reports
- Vol. 73 (3) , 1-77
U.S. Selected Practice Recommendations for Contraceptive Use, 2024
This report describes updated recommendations for contraceptive use.
- 8 August 2024
- Published by Centers for Disease Control MMWR Office in MMWR. Recommendations and Reports
- Vol. 73 (3) , 1-77
Top Cited PapersOpen AccessU.S. Selected Practice Recommendations for Contraceptive Use, 2024
This report describes updated recommendations for contraceptive use.
- 7 December 2023
- Published by Elsevier in Women's Health Issues
- Vol. 34 (2) , 186-196
Changes in Commercial Insurance Claims for Contraceptive Services During the Beginning of the COVID-19 Pandemic—United States, January 2019–September 2020
- 7 December 2023
- Published by Elsevier in Women's Health Issues
- Vol. 34 (2) , 186-196
Changes in Commercial Insurance Claims for Contraceptive Services During the Beginning of the COVID-19 Pandemic—United States, January 2019–September 2020
- Open Access
- 11 March 2022
- Published by Elsevier in Journal of Adolescent Health
- Vol. 70 (4) , S40-S41
77. Quality of Sexual and Reproductive Health Services for Adolescents: Findings from A Survey of U.S. Physicians
- 11 March 2022
- Published by Elsevier in Journal of Adolescent Health
- Vol. 70 (4) , S40-S41
Open Access77. Quality of Sexual and Reproductive Health Services for Adolescents: Findings from A Survey of U.S. Physicians
- Open Access
- 21 May 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (20) , 739-743
Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
This report describes updated recommendations for the use of self-administered injectable contraception.
- 21 May 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (20) , 739-743
Open AccessUpdate to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
This report describes updated recommendations for the use of self-administered injectable contraception.
- 4 March 2021
- Published by SAGE Publications in Journal of Women's Health
- Vol. 30 (3) , 293-300
Removing Unnecessary Medical Barriers to Contraception: Celebrating a Decade of the U.S. Medical Eligibility Criteria for Contraceptive Use
In 2010, the Centers for Disease Control and Prevention (CDC) released the U.S. Medical Eligibility Criteria for Contraceptive Use, providing recommendations for health care providers on safe use of contraception for people with certain characteristics or medical conditions. Adapted from World Health Organization guidance, the goal of the recommendations is to remove unnecessary medical barriers to contraception. Over the past decade, CDC has updated recommendations based on new evidence, collaborated with national partners to disseminate and implement the guidelines, and conducted provider surveys to assess changes in attitudes and practices around contraception safety and provision. CDC remains committed to supporting evidence-based guidelines for safe use of contraception, as the basis for improving access to contraception and high-quality family planning services, reducing unintended pregnancy, and improving reproductive health in the United States.
- 4 March 2021
- Published by SAGE Publications in Journal of Women's Health
- Vol. 30 (3) , 293-300
Removing Unnecessary Medical Barriers to Contraception: Celebrating a Decade of the U.S. Medical Eligibility Criteria for Contraceptive Use
In 2010, the Centers for Disease Control and Prevention (CDC) released the U.S. Medical Eligibility Criteria for Contraceptive Use, providing recommendations for health care providers on safe use of contraception for people with certain characteristics or medical conditions. Adapted from World Health Organization guidance, the goal of the recommendations is to remove unnecessary medical barriers to contraception. Over the past decade, CDC has updated recommendations based on new evidence, collaborated with national partners to disseminate and implement the guidelines, and conducted provider surveys to assess changes in attitudes and practices around contraception safety and provision. CDC remains committed to supporting evidence-based guidelines for safe use of contraception, as the basis for improving access to contraception and high-quality family planning services, reducing unintended pregnancy, and improving reproductive health in the United States.
- 1 February 2021
- Published by Elsevier in Contraception
- Vol. 103 (2) , 66-74
Patient and pharmacist perspectives on pharmacist-prescribed contraception: A systematic review
- 1 February 2021
- Published by Elsevier in Contraception
- Vol. 103 (2) , 66-74
Patient and pharmacist perspectives on pharmacist-prescribed contraception: A systematic review
- Open Access
- 9 January 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 46 (1) , 17-25
Copper intrauterine device use and HIV acquisition in women: a systematic review
Objectives To review systematically copper intrauterine device (Cu-IUD) use and HIV acquisition in women. Methods We searched Pubmed, Embase and the Cochrane Library between database inception and 26 June 2019 for longitudinal studies comparing incident HIV infection among women using an unspecified IUD or Cu-IUD compared with non-hormonal or no contraceptive users, or hormonal contraceptive users. We extracted information from included studies, assessed study quality, and summarised study findings. Results From 2494 publications identified, seven met our inclusion criteria. One randomised controlled trial (RCT), judged “informative with few limitations”, found no statistically significant differences in HIV risk between users of the Cu-IUD and either intramuscular depot medroxyprogesterone acetate (DMPA-IM) or levonorgestrel implant. One observational study, deemed “informative but with important limitations”, found no statistically significant difference in HIV incidence among IUD users compared with women who had tubal ligation or who were not using any contraception. Another “informative but with important limitations” observational study found no difference in HIV incidence between Cu-IUD users and DMPA or norethisterone enanthate injectable, or implant users. An RCT considered “unlikely to inform the primary question” also found no difference in HIV risk between Cu-IUD and progestogen-only injectable users. Findings from the other three “unlikely to inform the primary question” cohort studies were consistent with the more robust studies suggesting no increased risk of HIV acquisition among Cu-IUD users. Conclusion The collective evidence, including that from a large high-quality RCT, does not indicate an increased risk of HIV acquisition among users of Cu-IUDs.
- 9 January 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 46 (1) , 17-25
Open AccessCopper intrauterine device use and HIV acquisition in women: a systematic review
Objectives To review systematically copper intrauterine device (Cu-IUD) use and HIV acquisition in women. Methods We searched Pubmed, Embase and the Cochrane Library between database inception and 26 June 2019 for longitudinal studies comparing incident HIV infection among women using an unspecified IUD or Cu-IUD compared with non-hormonal or no contraceptive users, or hormonal contraceptive users. We extracted information from included studies, assessed study quality, and summarised study findings. Results From 2494 publications identified, seven met our inclusion criteria. One randomised controlled trial (RCT), judged “informative with few limitations”, found no statistically significant differences in HIV risk between users of the Cu-IUD and either intramuscular depot medroxyprogesterone acetate (DMPA-IM) or levonorgestrel implant. One observational study, deemed “informative but with important limitations”, found no statistically significant difference in HIV incidence among IUD users compared with women who had tubal ligation or who were not using any contraception. Another “informative but with important limitations” observational study found no difference in HIV incidence between Cu-IUD users and DMPA or norethisterone enanthate injectable, or implant users. An RCT considered “unlikely to inform the primary question” also found no difference in HIV risk between Cu-IUD and progestogen-only injectable users. Findings from the other three “unlikely to inform the primary question” cohort studies were consistent with the more robust studies suggesting no increased risk of HIV acquisition among Cu-IUD users. Conclusion The collective evidence, including that from a large high-quality RCT, does not indicate an increased risk of HIV acquisition among users of Cu-IUDs.